Furthermore, UBE2O overexpression predicts poor clinical outcomes and correlates with Mxi1 downregulation in lung cancer tissues, indicating that targeting the UBE2O/Mxi1 axis may be an attractive therapeutic strategy for treating lung cancer. This evidence concerns the gene UBE2O and lung cancer.